| Parameters | Values |
| Age |
|
| Median (range) | 52 [26 - 83] |
| WHO PSa |
|
| 0 | 47 (35.4%) |
| 1 | 78 (58.6%) |
| 2 | 8 (6%) |
| Histological subtype |
|
| SCCb | 122 (91.7%) |
| Adenocarcinoma | 8 (6%) |
| Others | 3 (2.3%) |
| Tumor size |
|
| Median (range) | 6 [3 - 13] |
| RLNc metastasis |
|
| Absence | 73 (54.9%) |
| Pelvic only | 46 (34.6%) |
| Lombo-aortic +/− Pelvic | 14 (10.5%) |
| FIGO stage |
|
| I-II | 49 (36.8%) |
| III-IVA | 84 (63.2%) |
| Hbd level |
|
| Median (range) | 11.2 [3.9 - 15.5] |
| Total dose to the tumor |
|
| Mean (range) | 69.6 [66-70] |
| Use of concurrent chemotherapy |
|
| Yes | 126 (94.7%) |
| No | 7 (5.3%) |
| Overall treatment time (in days) |
|
| Median | 60 [49 - 109] |
| Response to treatment (at the first follow-up visit) |
|
| Complete | 107 (80.5%) |
| Partial | 18 (13.5%) |
| Progression | 8 (6%) |